Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial.
Brener SJ, Lincoff AM, Bates ER, Jia G, Armstrong PW, Guetta V, Hochman JS, Savonitto S, Wilcox RG, White HD, Topol EJ; GUSTO V Investigators. Brener SJ, et al. Among authors: wilcox rg. Am Heart J. 2005 Jul;150(1):89-93. doi: 10.1016/j.ahj.2005.01.030. Am Heart J. 2005. PMID: 16084153
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial.
Nallamothu BK, Bates ER, Hochman JS, Granger CB, Guetta V, Wilcox RG, White HD, Armstrong PW, Savonitto S, Jia G, Lincoff AM, Topol EJ; GUSTO-V Investigators. Nallamothu BK, et al. Among authors: wilcox rg. Eur Heart J. 2005 Aug;26(15):1506-12. doi: 10.1093/eurheartj/ehi181. Epub 2005 Mar 30. Eur Heart J. 2005. PMID: 15800019 Clinical Trial.
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries.
Hasdai D, Holmes DR Jr, Topol EJ, Berger PB, Criger DA, Hochman JS, Bates ER, Vahanian A, Armstrong PW, Wilcox R, Ohman EM, Califf RM. Hasdai D, et al. Eur Heart J. 1999 Jan;20(2):128-35. doi: 10.1053/euhj.1999.1282. Eur Heart J. 1999. PMID: 10099909 Clinical Trial.
Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, Aylward P, Simes J, Dalby A, Betriu A, Bode C, White HD, Hochman JS, Emanuelson H, Vahanian A, Sapp S, Stebbins A, Moliterno DJ, Califf RM. Topol EJ, et al. Circulation. 2000 Oct 10;102(15):1761-5. doi: 10.1161/01.cir.102.15.1761. Circulation. 2000. PMID: 11023929 Clinical Trial.
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ. Mak KH, et al. Among authors: wilcox rg. J Am Coll Cardiol. 1997 Jul;30(1):171-9. doi: 10.1016/s0735-1097(97)00118-6. J Am Coll Cardiol. 1997. PMID: 9207639 Free article. Clinical Trial.
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial.
Simes RJ, O'Connell RL, Aylward PE, Varshavsky S, Diaz R, Wilcox RG, Armstrong PW, Granger CB, French JK, Van de Werf F, Marschner IC, Califf R, White HD; HERO-2 Investigators. Simes RJ, et al. Among authors: wilcox rg. Am Heart J. 2010 Jun;159(6):988-97. doi: 10.1016/j.ahj.2009.12.044. Am Heart J. 2010. PMID: 20569711 Clinical Trial.
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J, Lincoff AM, DeSmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ; REPLACE-2 Investigators. Saw J, et al. Among authors: wilcox rg. J Am Coll Cardiol. 2004 Sep 15;44(6):1194-9. doi: 10.1016/j.jacc.2004.06.049. J Am Coll Cardiol. 2004. PMID: 15364319 Free article. Clinical Trial.
119 results